Anti-arrhythmic properties of n-3 polyunsaturated fatty acids, at least in part mediated by anti-oxidant, anti-inflammatory and anti-fibrotic power, have been widely proved. Effect of fish oil on atrial fibrillation, both in primary and in secondary prevention and after cardiac surgery, are controversial, mostly due to lack of homogeneity between studies but also due to individual variability in response to fatty acids administration. Inclusion of measurement of incorporation of fish oil into cell membranes, appears to be essential in future studies, to assess their antiarrhythmic effect.
INTRODUCTION
N-3 poly-unsaturated fatty acids (PUFA) anti-arrhythmic effects have been debated for several years, since their electrophysiological properties have been recognized.
Through direct interaction with membrane bound proteins and thanks to incorporation into the phospholipid bilayer, n-3 PUFA are well known to influence ion channels and transmembrane pumps [1] to modulate signal transduction, protein trafficking and ion channels kinetic and to regulate gene expression [2] . N-3 PUFA can also exert anti- inflammatory effects by antagonizing pro-inflammatory prostaglandin formation [2] , and exert anti-fibrotic effects [3] , as well as cardiac autonomic modulation [4] . In particular, the influence of n-3 PUFA on atrial fibrillation (AF) primary and secondary prevention, including post-operative AF (POAF) has also been the object of numerous clinical studies.
EDITORIAL

N-3 PUFA in primary and secondary prevention and in POAF
Primary prevention: With regard to primary prevention of AF (Table 1) , two studies involving elderly subjects [5, 6] and one focusing on patients affected by acute myocardial infarction [7] proved n-3 PUFA to be protective against AF, while other studies [8] [9] [10] [11] [12] , showed no benefit. The influence of various diet habits, including fish consumption [8, 9] , can possibly explain different results, as well as different methodologies used for assessment of fish intake and for AF diagnosis. In particular, positive studies, generally included elderly individuals [5] [6] [7] , suggesting benefit from antifibrotic properties of fishoil. However, a post-hoc analysis of the randomized controlled trial GISSI-HF [13] showed no effect of longterm PUFA administration on AF development in heart failure patients, thus allowing no conclusions for the role of n-3 PUFA in AF primary prevention.
Post-operative AF:
The effect of n-3 PUFA in the context of POAF, that is characterized by inflammation, electrolyte disturbances and hemodynamic instability secondary to cardiac surgery, have also been also widely investigated. An open label study [14] firstly observed a short-term n-3 PUFA administration-related decrease in POAF incidence after coronary artery bypass grafting. Two papers [15, 16] also gained benefit from various fishoil preparations and administration timings (Table 2) . A recent randomized-controlled trial (RCT) [17] also observed reduction of POAF with n-3 PUFAs plus vitamins C and E administration in comparison to placebo, in 203 patients scheduled for cardiac surgery. Further studies however, failed to prove both prevention of AF [18, 19] and decrease of inflammation [20] from higher serum levels of n-3 PUFA, eicosapentaenoic acid (EPA), or docosahexaenoic acid (DHA), and from higher n3-PUFA atrial content [21, 22] . Recently, the multicenter double-blind RCT "OPERA" [23] showed no influence on POAF occurrence, from shortterm n3-PUFA administration. The effect was unrelated to patients characteristics, kind of cardiac-surgery, antiarrhythmic drugs, fish intake and serum n-3 PUFA. In a substudy of this trial indeed [24] , including 564 subjects receiving short-term PUFA or placebo before surgery, the risk of POAF was unrelated to fish oil concentrations at enrollment and day of surgery. Interestingly, PUFA increase, was characterized by significant inter-individual variableness (0.7%-7.5% after 5 d of supplementation). Finally, Metcalf et al [25] , by using combined data from previous RCTs, demonstrated less incidence of POAF among subject within the fourth quintile of red blood cell [7] 3242 subjects affected by acute myocardial infarction; age: 54. No AF risk reduction in the top vs the lowest tertile of fish intake Post-hoc analysis of a RCT (Aleksova) [13] 5835 systolic heart failuresubjects n-3 DHA, thus suggesting a U-shaped relation between n-3 PUFA intake and POAF. Four recent meta-analyses of the previously presented studies showed in turn, overall protective or neutral effect on POAF from n-3 PUFA [26] [27] [28] [29] ( Table 3) . Of note, none of these meta-analyses has assessed n-3 PUFA treatment duration to surgery as a covariate in a meta-regression analysis (Figure 1 ). Dissimilarities may be explained by various study designs and populations, AF definitions, cardiac surgery, co-administration of anti-arrhythmic or anti-inflammatory drugs, dietary PUFA intake, EPA/DHA ratios and fish oil-administration modes (i.e., intravenous or through nasogastric tube) and fish-oil administration time courses. Conversely, no effects of n-3 PUFA administration on myocardial infarction and bleeding after cardiac surgery, eventually influencing POAF occurrence, have been demonstrated [27] . Interestingly, all RCTs that failed to demonstrate a beneficial effect, used a formulation containing 1.24 EPA: DHA ratio [18, 20, 23] . In contrast, Rodorigo et al [17] administered PUFA with an EPA:DHA ratio equal to 0.5.
Secondary prevention:
Several studies have finally investigated the effect on n-3 PUFA on relapses of 116 February 26, 2016|Volume 8|Issue 2| WJC|www.wjgnet.com Table 2 Principal clinical studies investigating the effect of n-3 poly-unsaturated fatty acids on post-operative atrial fibrillation paroxysmal and persistent AF. Two studies [30, 31] , found fish oil administration (from 1 mo before, to 6 mo after cardioversion) helpful in AF prevention (Table 4) . On the other hand, 4 further studies [32] [33] [34] [35] failed to prove any effect. A recent study [36] including 337 patients with symptomatic paroxysmal/persistent AF, randomized to receive fish oil (4 g/d) or placebo, showed no difference in time to first AF recurrence, as well as no significant decrease of inflammatory markers at 6 mo. Similarly, another RCT [37] , proved no effect from n-3 PUFA on the time to AF relapses, as well as on concentrations of biomarkers of oxidative stress and inflammation and at follow-up. In particular, a large RCT [34] involving 586 patients with symptomatic paroxysmal or persistent AF, randomized to n-3 PUFA (1 g/d) vs placebo for 1 year, also proved no significant differences between the two arms, in terms of symptomatic recurrence of AF.
Contrasting outcomes between studies may be related to differences in PUFA somministration and populations characteristics. Generally, papers including subjects with more evident cardiac disease [30] , more often co-administered with amiodarone [30] showed benefit. Of note, some unfavorable papers proved AF relapses to occur mostly within 3 wk, prior
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Randomized, open label [14] 160 formulations and time courses. Moreover, a great variability in n-3 PUFA serum concentrations between subjects, despite similar fish-oil administration, has been recently proved, likely secondary to genetic predisposition in PUFA metabolism. Noteworthy, however, a recent RCT [38] examined the effects of high (6 g/d) or medium dose (3 g/d) fish oil supplementation, with or without multivitamin, on the inclusion of n-3 and n-6 PUFA within membranes of red blood cells after 16 wk. The authors found all treatments effective in increasing EPA composition of cell membranes to an eventual effect from n-3 PUFA.
DISCUSSION
The effect of n-3 PUFA on AF primary and secondary prevention and after cardiac surgery, remains controversial. A major reason for this uncertainty, is to be found in differences between studies, in particular regarding study designs, patients characteristics, AF definition and types (lone, vagally/adrenergically induced, secondary to structural disease), fish oil-administration modes, Table 4 Clinical studies investigating the effect of n-3 poly-unsaturated fatty acids on secondary prevention for atrial fibrillation Table 3 Recent metaanalises of studies of n-3 poly-unsaturated fatty acids in post-operative atrial fibrillation
Ref. Clinical setting NO. of studies and of patients Results
Costanzo et al [26] POAF 8 RCTs/2687 pts AF reduction Benedetto et al [27] POAF 431 pts No AF reduction; at meta-regression analysis: Trend toward a benefit from PUFA for administration of EPA/DHA ratio = 1:2 Zhang et al [28] POAF 8 RCT/2687 pts No AF reduction Ali-Hassan-Sayegh et al [29] POAF 23 RCTs/4278 pts AF reduction
RCTs: Randomized controller trials; pts: Patients; PO: Post-operative; AF: Atrial fibrillation; PUFA: Poly-unsaturated fatty acids; EPA: Eicosapentaenoic acid; DHA: Docosahexaenoic acid.
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Double blind-RCT [30] 109 pts, age: 70 yr; Italy; heart structural abnormality: 90%; Amiodarone + ACE-i/ARBs: 100% [37] 190 pts with paroxysmal or persistent AF N-3 PUFAs (4 g/d; n = 126) or placebo (n = 64) in a 2:1 ratio No PUFA dosage Not specified No reduction of AF recurrence and inflammation markers Double blind-RCT [34] 586 pts with symptomatic paroxysmal AF requiring ECV (n = 428), at least 2 episodes of AF in the 6 mo before (n = 55), or both in females, but not in males, for whom the higher dose n-3 PUFA plus multivitamin combination was necessary. As a consequence, discrepancies between trials could be partially related to individual capability of n-3 PUFA incorporation, which in turn, could be influenced by sex, age, vitamin and/or drug administration. To counteract the variability in response to fish oil administration, inclusion of blood measures of n-3 PUFA status appears therefore to be essential in future studies. The "Omega-3 Index" is the percentage of PUFA composed of EPA + DHA in red blood cell membranes [39] may represent a measurement of clinical utility to assess individual response to fish oil intake. Moreover, it may contribute to better understand the pharmacokinetics and pharmacodynamics of PUFA. Considering the results of recent studies showing an U-curve relationship between PUFA concentrations and AF [19, 25] , the greater protection from AF could be obtained from an individually-targeted approach for fish oil inclusion within membranes.
CONCLUSION
The complexity of the biological interactions of n-3 PUFA, their incorporation into cell membranes and the variability of clinical contexts, likely justify why PUFA administration does not automatically lead to AF reduction. RCTs focusing on clinical contexts of AF, and characterized by more accurate follow-ups and definitions of PUFA incorporation into red blood cells (or hopefully, in atrial tissue in the setting of cardiac surgery), are required. The RCT NCT00692718, will hopefully add information regarding fish oil effect on AF prevention in the context of HF and/or AMI. 
